Synthetic high-density lipoprotein-like nanoparticles for cancer therapy

Expert Review of Anticancer Therapy

Volumn 15, Issue 1, 2014, Pages 27-34

  Foit, Linda ^a,b   Giles, Francis J ^c   Gordon, Leo I ^a   Thaxton, Colby Shad ^a,b,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Institute for BioNanotechnology and Medicine (IBNAM)   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cancer; cholesterol; drug delivery; high density lipoprotein; nucleic acids; scavenger receptor

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BIS(NAPHTHALOCYANINE)GADOLINIUM; DNA; DOXORUBICIN; FOLATE RECEPTOR 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; NANOPARTICLE; PHOTOTHERMAL AGENT; PROTEIN BCL 2; PYROPHEOPHORBIDE; RADIOSENSITIZING AGENT; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; HIGH DENSITY LIPOPROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BCL 2 GENE; BINDING AFFINITY; CANCER CELL; CANCER CELL LINE; CANCER THERAPY; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENCAPSULATION; HUMAN; HYDROPHOBICITY; LIPOPHILICITY; LIVER CELL CARCINOMA; NEXT GENERATION SEQUENCING; NONHUMAN; PHOTOTHERAPY; PHOTOTHERMAL THERAPY; SCALE UP; CHEMISTRY; MOLECULARLY TARGETED THERAPY;

DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, HDL; MOLECULAR TARGETED THERAPY; NANOPARTICLES;

EID: 84919783401     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.990889     Document Type: Article

References (81)

1. Cruz PM, Mo H, McConathy WJ, et al. The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol 2013;4:119. An informative review detailing the role of cholesterol in cancer.
2. Gorin A, Gabitova L, Astsaturov I. Regulation of cholesterol biosynthesis and cancer signaling. Curr Opin Pharmacol 2012;12(6):710-16
3. Brown AJ. Cholesterol, statins and cancer. Clin Exp Pharmacol P 2007;34(3):135-41
4. Simons K, Ikonen E. How cells handle cholesterol. Science 2000;290(5497):1721-6
5. Simons K, Gerl MJ. Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Bio 2010;11(10):688-99
6. Clendening JW, Pandyra A, Boutros PC, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 2010;107(34):15051-6
7. Ginestier C, Monville F, Wicinski J, et al. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012;30(7): 1327-37
8. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232(4746):34-47
9. Olson RE. Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J Nutr 1998; 128(2):439s-43s
10. Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980;21(7):789-853
11. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000;30(3): 141-5
12. Mehta R, Gurudath S, Dayansoor S, et al. Serum lipid profile in patients with oral cancer and oral precancerous conditions. Dental Res J 2014;11(3):345-50
13. Muntoni S, Atzori L, Mereu R, et al. Serum lipoproteins and cancer. Nutrition Metabol Cardiovasc Dis 2009;19(3):218-25
14. Niendorf A, Nagele H, Gerding D, et al. Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer 1995;61(4):461-4
15. Leon CG, Locke JA, Adomat HH, et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010; 70(4):390-400
16. Shahzad MMK, Mangala LS, Han HD, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011; 13(4):309-U142. One of the first manuscripts to describe the use of high-density lipoproteins (HDLs) for nucleic acid delivery.
17. Llaverias G, Danilo C, Mercier I, et al. Role of cholesterol in the development and progression of breast cancer. Am J Pathol 2011;178(1):402-12
18. Danilo C, Gutierrez-Pajares JL, Mainieri MA, et al. Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res 2013;15(5):R87
19. Rotheneder M, Kostner GM. Effects of low-and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines. Int J Cancer 1989;43(5):875-9
20. Uda S, Accossu S, Spolitu S, et al. A lipoprotein source of cholesteryl esters is essential for proliferation of CEM-CCRF lymphoblastic cell line. Tumour Biol 2012; 33(2):443-53
21. Danilo C, Frank PG. Cholesterol and breast cancer development. Curr Opin Pharmacol 2012;12(6):677-82
22. Navab M, Reddy ST, Van Lenten BJ, et al. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009;50(Suppl): S145-9
23. Eren E, Yilmaz N, Aydin O. High density lipoprotein and it's dysfunction. Open Biochem J 2012;6:78-93
24. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biol 2011;13(4):423-33. This manuscript demonstrates, for the first time, that natural HDLs bind, stabilize and transport miRNAs.
25. Vickers KC, Remaley AT. Functional diversity of HDL cargo. J Lipid Res 2013; R035964
26. Jonas A, Phillips MC. Lipoprotein structure. N Comp Bioc 2008;485-506
27. Oram JF, Vaughan AM. ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006; 99(10):1031-43
28. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011;22(3): 176-85
29. Aslan B, Ozpolat B, Sood AK, Lopez-Berestein G. Nanotechnology in cancer therapy. J Drug Target 2013;21(10): 904-13
30. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3(1):16-20
31. Sabnis N, Lacko AG. Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Delivery 2012;3(5):599-608
32. Huynh E, Zheng G. Engineering multifunctional nanoparticles: all-in-one versus one-for-all. Wiley interdisciplinary reviews. Nanomed Nanobiotechnol 2013; 5(3):250-65
33. Ng KK, Lovell JF, Zheng G. Lipoprotein-Inspired Nanoparticles for Cancer Theranostics. Accounts Chem Res 2011;44(10):1105-13
34. Sabnis N, Nair M, Israel M, et al. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomed 2012;7: 975-83
35. Luthi AJ, Zhang H, Kim D, et al. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano 2012;6(1):276-85
36. Ng KK, Lovell JF, Vedadi A, et al. Self-Assembled Porphyrin Nanodiscs with Structure-Dependent Activation for Phototherapy and Photodiagnostic Applications. ACS Nano 2013;7(4):3484-90
37. Nakayama T, Butler JS, Sehgal A, et al. Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther 2012;20(8):1582-9
38. Zheng Y, Liu YY, Jin HL, et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics 2013;3(7): 477-86
39. Corbin IR, Ng KK, Ding L, et al. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine 2013;8(6): 875-90
40. Rui MJ, Tang HL, Li Y, et al. Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. Pharmaceutical Res 2013;30(5): 1203-14
41. Fischer NO, Weilhammer DR, Dunkle A, et al. Evaluation of Nanolipoprotein Particles (NLPs) as an In Vivo Delivery Platform. PloS One 2014;9:3. A comprehensive analysis of variations of nanoparticle synthesis and conjugation chemistries is presented. In addition, the authors investigate the toxicity profile of recombinant HDLs.
42. Wang BL, Yuan Y, Han L, et al. Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma. J Drug Target 2014;22(1):76-85
43. Kim Y, Fay F, Cormode DP, et al. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano 2013;7(11):9975-83. This paper shows a microfluidic platform for the scale-up and manufacturing of a variety of synthetic HDLs.
44. Bricarello DA, Smilowitz JT, Zivkovic AM, et al. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano 2011;5(1):42-57
45. Sabnis N, Pratap S, Akopova I, et al. Pre-clinical evaluation of rHDL encapsulated retinoids for the treatment of neuroblastoma. Front Pediatr 2013;1:6
46. Yuan Y, Wang WN, Wang BL, et al. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 2013;21(4):367-74
47. Lin Q, Chen J, Ng KK, et al.Like Nanoparticles. Pharmaceutical Res 2013; 31(6):1438-49
48. Reddy ST, Navab M, Anantharamaiah GM, Fogelman AM. Searching for a successful HDL-based treatment strategy. Biochim Biophys Acta 2014;1841(1):162-7
49. Knecht TP, Pittman RC. A plasma-membrane pool of cholesteryl esters that may mediate the selective uptake of cholesteryl esters from high-density lipoproteins. Biochim Biophys Acta 1989; 1002(3):365-75
50. Pittman RC, Knecht TP, Rosenbaum MS, Taylor CA. A nonendocytotic mechanism for the selective uptake of high-density lipoprotein-associated cholesterol esters. J Biol Chem 1987;262(6):2443-50
51. Corbin IR. Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery. Methods Mol Biol 2013;1049:467-80
52. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108(3):619-26
53. Liadaki KN, Liu T, Xu S, et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem 2000;275(28):21262-71
54. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116(12): 3090-100
55. Jia JT, Xiao Y, Liu JP, et al. Preparation, characterizations, and in vitro metabolic processes of paclitaxel-loaded discoidal recombinant high-density lipoproteins. J Pharm Sci-Us 2012;101(8):2900-8
56. Wang J, Jia JT, Liu JP, et al. Tumor targeting effects of a novel modified paclitaxel-loaded discoidal mimic high density lipoproteins. Drug Deliv 2013; 20(8):356-63
57. Zhang M, Jia J, Liu J, et al. A novel modified paclitaxel-loaded discoidal recombinant high-density lipoproteins: preparation, characterizations and in vivo evaluation. Asian J Pharmaceutical Sci 2013;8(1):11-18
58. Wagner J, Riwanto M, Besler C, et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arteriosclerosis Thrombosis Vasc Biol 2013;33(6):1392-400
59. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18(10):997-1006
60. Rayner KJ, Hennessy EJ. Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res 2013;54(5):1174-81
61. Chen X, Liang H, Zhang J, et al. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 2012;3(1):28-37
62. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prevent Res 2012;5(3): 492-7
63. Ding Y, Wang W, Feng MQ, et al. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012; 33(34):8893-905
64. Lin QY, Chen J, Jin HL, et al. Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine 2012; 7(12):1813-25
65. Lin Q, Jin CS, Huang H, et al. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. Small 2014;10(15):3072-82
66. Krycer JR, Brown AJ. Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective. Biochim Biophys Acta 2013;1835(2):219-29
67. McMahon KM, Mutharasan RK, Tripathy S, et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett 2011;11(3):1208-14
68. Tripathy S, Vinokour E, McMahon KM, et al. High-density lipoprotein nanoparticles deliver RNAi to endothelial cells to inhibit angiogenesis. Part Part Syst Charact 2014; 31(11):1141-50
69. Dong Y, Love KT, Dorkin JR, et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci USA 2014;111(11):3955-60
70. Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999;10(3): 207-17
71. Van Eck M, Van Dijk KW, Herijgers N, et al. Essential role for the (hepatic) LDL receptor in macrophage apolipoprotein E-induced reduction in serum cholesterol levels and atherosclerosis. Atherosclerosis 2001;154(1):103-12
72. Mathew S, Murakami T, Nakatsuji H, et al. Exclusive photothermal heat generation by a gadolinium Bis(naphthalocyanine) complex and inclusion into modified high-density lipoprotein nanocarriers for therapeutic applications. ACS Nano 2013;7(10): 8908-16
73. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290(17): 2292-300
74. Easton R, Gille A, D'Andrea D, et al. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Pharmacol 2014;54(3):301-10
75. Keyserling CH, Hunt TL, Klepp HM, et al. CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers. Circulation 2011;124:21
76. Zhang Z, Cao W, Jin H, et al. Biomimetic nanocarrier for direct cytosolic drug delivery. Angew Chem 2009;48(48):9171-5
77. Su F, Grijalva V, Navab K, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 2012;11(6):1311-19
78. Yang S, Damiano MG, Zhang H, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Scie USA 2013;110(7):2511-16. This manuscript shows the inherent therapeutic potential of HDL NPs for the treatment of lymphoma. Uniquely, the mechanism of action is dependent on both biomimetic surface chemistry and the presence of the gold nanoparticle scaffold used to synthesize the HDL NPs.
79. Zamanian-Daryoush M, Lindner D, Tallant TC, et al. The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem 2013; 288(29):21237-52
80. Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009;1(1): 29-43
81. Yang M, Chen J, Cao W, et al. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold. Nanomedicine 2011;6(4): 631-41